For research use only. Not for therapeutic Use.
Firivumab（Cat No.:I042102）is an investigational monoclonal antibody being developed to target and neutralize the respiratory syncytial virus (RSV), a common cause of respiratory infections, particularly in infants, elderly individuals, and immunocompromised patients. By binding to the virus’s surface proteins, firivumab prevents RSV from entering human cells and replicating. It is being studied as a potential treatment and preventive measure for RSV infections, especially for high-risk populations. Clinical trials are evaluating its safety, efficacy, and ability to reduce the severity of RSV-related symptoms and complications, offering hope for more effective RSV therapies.
| Catalog Number | I042102 |
| CAS Number | 1443004-15-6 |
| Purity | ≥95% |
